is anyone running this on its own or is it all CagriSema in here
#cagrilintide 2026-02-13
Friday51 messages10 participantstimes are UTC
Highlights from this day
- cagri_curious — is the nausea profile genuinely different or am i imagining it the fullness thing is the part people describe differently, food stops being interesting rather than… 13:49
- otto_swirls — nobody should copy my schedule, im describing it because people asked what a slow ramp looks like 14:21
- otto_swirls — €240 for a 20 vial and it lasts me longer than the GLP-1 does at my doses 14:36
- cagri_curious — unrelated but did anyone find monotherapy underwhelming the fullness thing is the part people describe differently, food stops being interesting rather than repellent 14:43
- VialBot — New independent result logged — MKM, lot H-2814, purity 98.6% (Janoshik). 16:00
monotherapy was underwhelming for me and i say that as someone who wanted it to work
underwhelming honestly
cant separate them
thats the phase 3 one
held mine a while
is the nausea profile genuinely different or am i imagining it
the fullness thing is the part people describe differently, food stops being interesting rather than repellent
14:02quiet.hours pinned a message
slower than the others
the nausea felt different rather than less, more fullness and less of the queasy wave, i could be wrong
[edited]has REDEFINE reported or are people quoting earlier work
titrating dead slow
amylin not glp-1
nobody should copy my schedule, im describing it because people asked what a slow ramp looks like
🤝14
€240 for a 20 vial and it lasts me longer than the GLP-1 does at my doses
📈17🧪5
the fullness effect hasnt faded over 11 months, unlike my semaglutide appetite curve
REDEFINE is the trial
👍4⚠️2
cagrisema thats it
whats REDEFINE testing exactly
unrelated but did anyone find monotherapy underwhelming
the fullness thing is the part people describe differently, food stops being interesting rather than repellent
separate days
📈10👀15👍4
added it to an existing cagrilintide dose rather than starting both, which made attribution possible
combination for me
fullness rather than nausea
🧪1🔥7
monotherapy here
noticed something around week 9 on monotherapy, well after i had given up expecting to
REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work
*Medutest not the other one
i keep the two on separate days so if something goes wrong i have a chance of knowing which
dosing them on different days made no difference i could detect
went slower because the first step gave me two rough days and i took that as information
New independent result logged — MKM, lot H-2814, purity 98.6% (Janoshik).
i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something
update on the earlier thing you cannot tell which of the two is doing what in a combination and i stopped pretending i could
the fullness thing is the part people describe differently, food stops being interesting rather than repellent, from memory
i titrated over twice as many weeks as i did on semaglutide and that was right for me
*week 7 not week 8
does amylin do something about fullness that the GLP-1 doesnt
different not less
👍7
weekly for me, same day every week, no reason beyond habit
the nausea felt different rather than less, more fullness and less of the queasy wave
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake
whats the recon people use, 40 in 2ml
17:58quiet.hours pinned a message
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist
held at 12 for 2 months on monotherapy before i touched it again
i was sceptical about monotherapy and after 19 months im still sceptical, just less so, from memory
the reason nausea reads differently is timing, mine arrived on the second day rather than the first
the slower titration in here is community habit as much as anything, the trials had their own schedule
changed my mind on this, i started thinking amylin was the interesting bit and now i think its the pairing
stopped for 10 months and the fullness went within a fortnight of the last dose, thats one data point
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing